ArticleBritish journal of pharmacology2017
Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor.
Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Understanding insulin-like peptide 5 (INSL5) and relaxin family peptide receptor 4 (RXFP4): structure, signalling, and function.RSC chemical biology · 2026Review
- Integration of signal transduction pathways in sensory epithelial enteroendocrine cells.Molecular biology of the cell · 2025Review
- Nobiletin mitigates benign prostatic hyperplasia by suppressing prostate cell proliferation through regulation of cell cycle progression, signaling pathways, transcription factor activity, and the androgen-signaling axis.Frontiers in pharmacology · 2025Article
- Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.Medicina (Kaunas, Lithuania) · 2023Review
- Ligand recognition mechanism of the human relaxin family peptide receptor 4 (RXFP4).Nature communications · 2023Article
- A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function.ACS pharmacology & translational science · 2021Article
- Review
- Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling.EMBO molecular medicine · 2020Article
- Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model.Frontiers in endocrinology · 2020Article
- Convergent gene losses illuminate metabolic and physiological changes in herbivores and carnivores.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Real-time examination of cAMP activity at relaxin family peptide receptors using a BRET-based biosensor.Pharmacology research & perspectives · 2018Article
- The Regulation of Peripheral Metabolism by Gut-Derived Hormones.Frontiers in endocrinology · 2018Review
- Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor.British journal of pharmacology · 2017Article
- Recent progress in the understanding of relaxin family peptides and their receptors.British journal of pharmacology · 2017Article
- The actions of relaxin family peptides on signal transduction pathways activated by the relaxin family peptide receptor RXFP4.Naunyn-Schmiedeberg's archives of pharmacology · 2017Article
Corrections and comments
- Erratum issuedCorrection.2017
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeInsulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin superfamily, uniquely expressed in enteroendocrine L-cells of the colon. It is the cognate ligand of relaxin family peptide RXFP4 receptor that is mainly expressed in the colorectum and enteric nervous system. This study identifies new signalling pathways activated by INSL5 acting on RXFP4 receptors. EXPERIMENTAL APPROACH: INSL5/RXFP4 receptor signalling was investigated using AlphaScreen® proximity assays. Recruitment of Gα KEY
resultsINSL5 inhibited forskolin-stimulated cAMP accumulation and increased phosphorylation of ERK1/2, p38MAPK, Akt Ser CONCLUSIONS AND IMPLICATIONS: Knowledge of signalling pathways activated by INSL5 at RXFP4 receptors is essential for understanding the biological roles of this novel gut hormone. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.